Hyperglycemia-mediated decrease in FOXO3A phosphorylation and increased total FOXO3A levels could be reversed upon lapatinib treatment (a dual inhibitor of EGFR and ErbB2 receptors) (Benter et al., 2015). Here, FOXO3 is linked to Hyperglycemia.